PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

• US 20110251208A1
• Filed: 11/23/2009
• Published: 10/13/2011
• Est. Priority Date: 11/25/2008
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Joens, Olaf, Daemmgen, Juergen
• Granted Patent: US 8,664,252 B2
• Time in Patent Office: Days
• US Class Current: 514/252.06
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/10 Sulfides; Sulfoxides; Sulfones
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/33 Heterocyclic compounds
• CPC Class Codes: A61K 31/4166 having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/4412 having oxo groups directly attached to the heterocyclic ring
• CPC Class Codes: A61K 31/444 containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• CPC Class Codes: A61K 31/501 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: C07D 237/04 having less than three double bonds between ring members or between ring members and non-ring members
• CPC Class Codes: C07D 403/04 directly linked by a ring-member-to-ring-member bond

Abstract

The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca²⁺- sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca²⁺-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.

Claims

1. Use of a phosphodiesterase type III (PDE III) inhibitor or a Ca²⁺-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from diastolic dysfunction.

2. Use according to claim 1, wherein the diastolic dysfunction is hypertrophic cardiomyopathy.

3. The use according to claim 1, wherein the PDE III inhibitor exhibits additionally calcium sensitising effects.

4. The use according to claim 1, wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is selected from the group consisting of pimobendan, milrinone, levosimendan, amrinone, enoximone, and piroximone.

5. The use according to claim 4, wherein the PDE III inhibitor is pimobendan.

6. The use according to claim 1, wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is utilized in oral or parenteral form.

7. The use according to claim 1, wherein the medicament is prepared in a form to be used in a dosage between 5 and 2,500 μ

g PDE III inhibitor or Ca²⁺-sensitizing agent per kg bodyweight per day.

8. The use according to claim 1, wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is administered in a daily dosage between 5 and 2,500 μ

g/kg bodyweight.

9. The use according to claim 1, wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is administered together with furosemide.

10. The use according to claim 9, wherein the furosemide is administered in a dosage between 0.5 to 5 mg/kg bodyweight once or twice daily.

11. The use according to claim 1, wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is selected from the group consisting of a β

L-type calcium channel blocker, a β

-adrenoreceptor antagonists, and an if-blocker.

12. The use according to claim 1, wherein said patient is a mammal selected from the group consisting of non-human primates, humans, dogs, cats and horses.

13. The use according to claim 12, wherein said patient is a cat.

14. A PDE III inhibitor or Ca²⁺-sensitizing agent for the treatment of a patient suffering from diastolic dysfunction.

15. A PDE III inhibitor or Ca²⁺-sensitizing agent for the treatment of a patient suffering from hypertrophic cardiomyopathy.